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Abstract
Background
Lifetime suicide attempts in patients with comorbidity between psychotic disorders and Sub-
stance Use Disorder (SUD), known as dual diagnosis, was associated with a worse clinical
and cognitive state, poor prognosis and premature death. However, to date no previous
study has examined the cognitive performance of these patients considering as indepen-
dent the presence or absence of lifetime suicide attempts.
Methods
We explore executive functioning differences between suicide attempters and non-attemp-
ters in dual schizophrenia (DS) patients and the possible related factors for both executive
performance and current suicide risk. Fifty DS male patients in remission of SUD and clini-
cally stables, 24 with and 26 without lifetime suicide attempts, were evaluated. We consid-
ered Z scores for all neuropsychological tests and a composite summary score for both
premorbid IQ and executive functioning.
Results
DS patients showed low performance in set-shifting, planning and problem solving tasks.
Those with suicide attempts presented lower composite summary scores, together with
worse problem solving skills and decision-making, compared with non-attempters. How-
ever, after controlling for alcohol dependence, only differences in decision-making re-
mained. Executive functioning was related to the premorbid intelligence quotient, and
several clinical variables (duration, severity, months of abstinence and relapses of SUD,
global functioning and negative symptoms). A relationship between current suicide risk, and
first-degree relatives with SUD, insight and positive symptoms was also found.
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Conclusions
Our results suggest that problem solving and, especially, decision-making tasks might be
sensitive to cognitive impairment of DS patients related to presence of lifetime suicide
attempts. The assessment of these executive functions and cognitive remediation therapy
when necessary could be beneficial for the effectiveness of treatment in patients with DS.
However, further research is needed to expand our findings and overcome some limitations
of this study.
Introduction
Substance Use Disorder (SUD) is becoming more prevalent over the years and it is highly com-
mon in Schizophrenia (SZ), a comorbidity known as Dual Schizophrenia (DS). This dual diagno-
sis has relevant clinical implications, given that substance use could exacerbate the SZ symptoms
[1] as well as the cognitive impairment [2, 3], it also worsens the prognosis of the disorder [4, 5],
and increases the risk of suicide [6]. Thus, it is necessary to study new ways to improve the
health-related quality of life and reducing mortality of DS patients. Given that suicide is one of
the main causes of premature death in SZ [7, 8], preventing suicide and diminishing its risk fac-
tors deserve great consideration as main targets of care, especially in the DS population.
Around 20–50% of SZ patients will attempt suicide in their lifetime [9, 10]. The suicide risk
is greater in first or acute psychotic episodes, during the first six months after hospitalization
[11, 12] and in SUD comorbid conditions [6, 8, 11, 13–16]. Alcohol is one of the most studied
substances since it has been shown to have a significant impact on suicide [17–19] and cogni-
tion [20, 21]. Furthermore, DS patients, compared to SUD patients, are less motivated to
change their consumption pattern, are more difficult to involve in treatment, exhibit slower
progress, tend to give up long-term programs [22] and remain at risk of relapse even years
after a period of full remission [23].
In addition to the SUD, other risk factors for suicide described in SZ patients are: male gen-
der, single marital status, living alone and social isolation, family or personal history of lifetime
suicide attempts, aggressive behavior, depression and hopelessness, low stress resistance,
higher insight and metacognition ability. Moreover, other factors are also linked to suicide risk
in SZ patients: low adherence to non-pharmacological treatment, more typical antipsychotic
prescriptions, long-term illness with several exacerbations, loss of faith in treatment, fear of
deterioration, higher insight of the illness, increased positive and fewer negative symptoms,
higher nicotine consumption and greater duration of untreated psychosis [17, 24, 25].
On the other hand, the study of the clinical characteristics of the DS patients highlights the
important role played by cognition. Compared with the single condition, in the DS it has been
observed a worse global cognitive state [26] with a marked deterioration with age, especially in
executive performance [2, 3, 27], and it is considered to be a powerful predictor of maladaptive
functioning [26]. Interestingly, higher premorbid intelligence quotient [17, 28], better execu-
tive [29, 30] and social premorbid functioning [18], and dysfunctional impulsivity [9, 19, 28]
have been hypothesized to predispose for suicidal behavior and could facilitate the illegal sub-
stance acquisition. In this context, the primary drug of dependence seems decisive given that
alcohol is the substance that has shown greater neurodegenerative brain effects and cognitive
impairment [31].
Taking all the factors stated above into consideration, DS individuals are a vulnerable popu-
lation to commit suicide, given that they meet many of the preconditions for the emergence of
suicidality. However, few studies have evaluated the executive functioning of the DS patients
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and none has addressed its possible influence on the existence of lifetime suicide attempts and
clinical variables that may be modulating results, so new research is needed to clarify these
questions.
The aim of this study was to explore, firstly, the executive functioning differences between
suicide attempters and non-attempters in DS patients and the possible premorbid and clinical
related factors. To do it an exhaustive clinical evaluation and a complete neuropsychological
battery was applied, being all patients in remission of SUD and clinically stables.
Materials and Methods
Participants
The participants were 50 DS male patients (36.06 ± 7.79 years) from seven medical centers in
Barcelona. They were assigned to two groups according to the self-reported previous suicide
attempts: DS attempters (DS+; n = 24) and DS non-attempters (DS-; n = 26). Our sample size
was aimed to have a balanced design in two groups. Both groups were abstinent for at least
three months, controlled by urinalysis.
Patients were derived by medical centers from their diagnoses according to the DSM-IV-
TR (2000) [32] and inclusion/exclusion criteria required. However, each diagnosis was con-
firmed in a first evaluation session by a researcher responsible for clinical assessment (Master
in Clinical Psychology) using the SCID-I and a structured interview of sociodemographic
and clinical data. Occasionally, some patients were ruled out for not complying with the dual
diagnosis required. The inclusion criteria were: (1) current diagnosis of psychotic spectrum
disorder (schizophrenia and schizoaffective) and current SUD in remission for at least three
months; (2) under treatment; (3) male gender, consistent with the sex prevalence of the
disorder; (4) age between 18–55 years; (5) clinically stable psychiatric symptomatology. The
exclusion criteria were: (1) DSM-IV-TR criteria for a current substance induced-psychiatric
disorder or psychiatric disorder due to a medical condition; (2) other severe medical illness;
(3) mental retardation, history of traumatic brain injury or neurological injury; (4) receiving
electroconvulsive therapy within 12 months prior to their study participation. From initially
derived sample (n = 56) six patients were discarded for failing to meet the diagnostic and clini-
cal criteria. None of the patients included in the study dropped out and they all completed data
recording sessions.
All patients were in treatment for their clinical conditions (SUD and psychotic disorder)
with an integrated intervention in which addiction and mental health intervention are offered
at the same time and by the same team [5]. Integrated intervention includes a combination of
motivational interviewing, contingence and case management, cognitive behavioral therapy,
social skills training and relapse prevention.
The ethic committee of the University of Barcelona approved this study, which complies
with the ethical standards on human experimentation and with the Helsinki declaration of
1975, as revised in 2008. All participants provided written informed consent and were not
compensated for their participation. Data collection was carried out between 2013 and 2015.
Clinical Measures
Information was collected using the Structural Clinical Interview for DSM-IV-TR Axis I
Disorders (SCID-I) [33] along with a structured interview of sociodemographic and clinical
data. We confirmed the self-reported data with the medical history of the medical centers,
with especial emphasis in our classificatory criteria of lifetime suicide attempts. The suicide
attempts in DS+ group range from 1 to 5, with the following distribution: 8 patients with
one attempt, 8 with two attempts, 5 with three attempts, 1 with four attempts and 2 with five.
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Chlorpromazine equivalent doses (CPZ) were calculated for antipsychotic medication [34].
We also recorded daily consumption of cigarettes and caffeine (milligrams of coffee, tea or
cola), and the Fagerstro¨m test [35] was administered to smokers for nicotine dependence.
Additionally, the Clinical Global Impression-Severity scale (CGI-S) [36] was applied as a
subjective measure of the clinical severity. The general level of symptoms and functioning was
assessed through the Global Assessment of Functioning (GAF) [37]. The Positive and Negative
Syndrome Scale (PANSS) [38] was administered as a measure of psychotic symptom severity,
and item 12 was used for Insight evaluation. Social adaptation was measured by the Social
Adaptation Self-Evaluation Scale (SASS) [39]. Depressive symptoms were assessed with the
Beck Depression Inventory (BDI) [40] and the Plutchik Risk of Suicide Scale (RS) [41] was
applied to assess the current suicide risk, establishing the cut-off of 6 points [42]. Finally, the
severity of the SUD was measured with the Drug Abuse Screening Test (DAST-20) [43].
Neuropsychological Assessment
We used the Vocabulary and Block Design subtests (WAIS-III) as a reliable estimate of verbal
and non-verbal premorbid IQ [44]. To obtain measures of dorsolateral prefrontal function we
selected the Backward Digits subtest (WAIS-III), the Trail Making Test -trail B- (TMT-B), the
Tower of Hanoi (ToH) and the standard computerized version of the Wisconsin Card Sorting
Test (WCST) as measures of working memory, set-shifting, planning abilities and problem
solving, respectively. The Iowa Gambling Task (IGT) was administered to measure decision-
making capacity, as a measure of dysfunctional impulsivity related to orbitofrontal cortex
functioning [45]. Raw scores were transformed to Z scores (mean = 0 ± SD = 1) for all tests
(global scores) and its subcomponents, based on the Spanish normative data for the WAIS-III
subtests [46], TMT-B [47, 48], WCST [49], on Mexican normative data for ToH [50], and on
American normative data for IGT [51]. An average of Z scores (composite summary scores)
were conducted to yield a general measure for both premorbid IQ and executive functioning.
Data Analysis
Group differences in demographic and clinical variables were explored with the Mann-Whit-
ney U test (U) or with the Chi-Square test for categorical variables. If the quantitative data ful-
filled the necessary conditions, the Student’s t-test (t) was used; when the conditions were not
met, the nonparametric Mann-Whitney U test was used instead. Differences in Z scores of
neuropsychological performance between groups were analyzed with one-way analysis of
covariance (ANCOVA) for Vocabulary, Block Design, Backward Digits subtests, TMT-B and
composite summary scores for both premorbid IQ and executive functioning. Multivariate
analysis of covariance (MANCOVA) was conducted in the case of the ToH, WCST and IGT.
Repeated measures multivariate analysis of variance (RM MANCOVA) was also used for the
five blocks of the IGT direct scores. In all cases, we considered age as covariate to control for
possible effects in cognitive performance because, although groups did not show differences,
are known the age-related effects both in general population [50] and DS patients [2, 3]. We
repeated all significant analyses including alcohol dependence also as covariate. The partial
squared Eta (ηp
2) statistic was used to measure the effect size, in conjunction with the observed
power through the option available in the analysis of variance, and the post-hoc comparisons
were Bonferroni corrected. Finally, we conducted stepwise linear regressions considering only
the significant variables (p< 0.05) found in a previous bivariate correlation analysis for execu-
tive functioning and current suicide risk. In all cases the conditions of application and non-
existence of collinearity and multicollinearity were verified. Data were analyzed using the Sta-
tistical Package for the Social Sciences (SPSS; version 21.0).
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Results
Demographic and Clinical Data
Groups did not differ in sociodemographic data, medical comorbidity, CPZ, CGI, GAF, depressive
symptoms, social adaptation, daily caffeine intake and current suicide risk scores (see Table 1).
Although no significant difference were found between groups in the suicide risk, considered as
present or absent (χ2(1) = 1.82; p = 0.18), we have observed a tendency of higher proportions of
patients with suicide risk in the DS+ (84.6%) compared to the DS- group (58.3%). Daily medica-
tion was equivalent between groups, except for use of interdictors, with higher consumption in the
DS+ group. Moreover, DS+ showed a higher number of first-degree relatives both with SUD and
psychiatric disorders, daily cigarette consumption and nicotine dependence compared to DS-. No
significant differences were found between groups in psychotic symptoms (PANSS scores).
Regarding SUD characteristics, polyconsumption was the more frequent pattern in the
total sample (72%) and also in both groups (DS+: 83% and DS-: 61%). DS+ patients showed
greater alcohol consumption than DS-, although the percentage of patients with the alcohol as
primary drug of dependence was not different between groups. Moreover, the two groups did
not show differences in length of abstinence, number of relapses, duration of SUD and severity
of SUD (DAST-20).
Executive Functioning
The total sample showed a low performance compared to the normative data in the TMT-B,
reaction time in the ToH, and trials to first category in WCST (z scores lower to -1SD). In the
other tasks, both in the individual components and global scores, as well as in the composite
summary score of executive functioning, performance tended to be worse than average but in
no case exceeds -1SD (Table 2).
The groups showed similar premorbid IQ, considering both the verbal component as the
manipulative, and only provided differences in the performance of WCST and IGT. The
WCST analyses showed significant worse scores for the DS+ patients in categories completed,
trials to first category and in the global measure of WCST performance. However, these differ-
ences disappeared when the alcohol dependence was considered as a covariate in the analyses
(F (1,46) < 2.229; p> 0.143; ηp
2 < 0.049).
Considering the IGT, we obtained significant differences in the third, fourth and last block
trials as well as in the total score (100 trials), with the DS+ group showing the worst perfor-
mance. Although the Z scores for both groups in the IGT were within the mean, when the total
direct scores were considered regarding the type of decision-making chosen, the DS+ group
showed a disadvantageous pattern in comparison to the DS- (F (1,47) = 11.274; p = 0.002; ηp
2 =
0.193; power = 0.907) (see Fig 1A). Similarly, the RM MANCOVA for the direct scores showed
a significantly worse performance of the DS+ group (F (1,47) = 5.203; p = 0.027; ηp
2 = 0.100;
power = 0.636), with a negative learning compared to the DS- (see Fig 1B). All significant differ-
ences between groups in the IGT remained when alcohol dependence was considered as a
covariate in the analyses (F (1,46) > 4.64; p< 0.037; ηp
2 > 0.092; power> 0.562).
Finally, the composite summary score of executive functioning was worse in DS+ group as
compared to DS- and it continued providing significant differences when in the analysis the alco-
hol dependence was included as covariate (F (1,46) = 4.982; p = 0.032; ηp
2 = 0.096; power = 0.603).
Factors Related to Executive Functioning and Current Risk of Suicide
In the total sample, the regression analysis indicated that the model was significant for all cog-
nitive tasks except the IGT, and also for the composite summary score of executive functioning
Suicide Attempts and Executive Functioning in Dual Schizophrenia
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Table 1. Sociodemographic and clinical data of Dual Schizophrenia (DS) patients, and considering the presence (DS+) or absence (DS-) of suicide
attempts. Mean, standard deviation, frequency with percentage, and statistical contrast (Student’s t, Mann-Whitney U or Chi-Square test).
DS (N = 50) DS- (N = 26) DS+ (N = 24) Statistical contrast
Sociodemographic data
Age (yr) 36.06 (7.79) 35.92 (8.63) 36. 21 (6.95) t(1,48) = 0.12
Marital status Χ2(2) = 2.48
Single 41 (82.0%) 22 (84.6%) 19 (79.2%)
Stable partner 3 (6.0%) 2 (7.7%) 1 (4.2%)
Separated/Divorced 6 (12.0%) 2 (7.7%) 4 (16.6%)
Years of education 9.84 (2.06) 9.38 (1.94) 10.33 (2.12) t(1,48) = 1.65
Economic situation χ2(4) = 2.68
Active 5 (10.0%) 2 (7.7%) 3 (12.5%)
Disability pension 35 (70.0%) 17 (65.4%) 18 (75.0%)
Unemployed 5 (10.0%) 3 (11.5%) 2 (8.3%)
No income 3 (6.0%) 2 (7.7%) 1 (4.2%)
Off work (on sick leave) 2 (4.0%) 2 (7.7%) 0 (0%)
Clinical data
Number of medical comorbidities 0.60 (0.81) 0.42 (0.58) 0.79 (0.96) t(1,48) = 1.64
Respiratory-type a 4 (8.0%) 3 (11.5%) 1 (4.2%) χ2(1) = 0.92
Metabolic-type a 7 (14.0%) 3 (11.5%) 4 (16.7%) χ2(1) = 0.27
Infectious-type a 6 (12.0%) 2 (7.7%) 4 (16.7%) χ2(1) = 0.95
Other a 9 (18.0%) 4 (15.4%) 5 (20.8%) χ2(1) = 1.43
Daily number of medications 3.20 (1.78) 2.96 (1.93) 3.46 (1.61) t(1,48) = 0.98
Typical antipsychotics a 13 (26.0%) 7 (26.9%) 6 (25.0%) χ2(1) = 0.02
Atypical antipsychotics a 45 (90.0%) 22 (84.6%) 23 (95.8%) χ2(1) = 1.00
Antidepressants a 15 (30.0%) 6 (23.1%) 9 (37.5%) χ2(1) = 2.33
Mood stabilizers a 12 (24.0%) 6 (23.1%) 6 (25.0%) χ2(1) = 0.07
Anxiolytics a 21 (42.0%) 9 (34.6%) 12 (50.0%) χ2(1) = 0.98
Anticholinergics a 13 (26.0%) 8 (30.8%) 5 (20.8%) χ2(1) = 0.78
Interdictor a 15 (30.0%) 4 (15.4%) 11 (45.8%) χ2(1) = 5.13*
Other medication a 14 (28.0%) 8 (30.8%) 6 (25.0%) χ2(1) = 0.64
CPZ equivalent dosage (mg) 41.34 (90.36) 35.32 (97.20) 45.37 (83.53) t(1,48) = 1.02
Clinical Global Impression 3.84 (1.48) 3.96 (1.40) 3.71 (1.57) t(1,48) = 0.60
Global Assessment Functioning 65.78 (10.82) 64.46 (10.17) 67.21 (11.52) t(1,48) = 0.89
Current suicide risk (Plutchik scale) 6.80 (2.41) 5.92 (1.93) 7.62 (2.60) t(1,48) = 1.18
Depressive symptoms (BDI) 4.53 (4.08) 3.80 (6.34) 4.83 (3.04) t(1,48) = 0.46
Social adaptation (SASS) 36.55 (9.06) 35.33 (9.92) 38.38 (7.87) t(1,48) = 0.76
Relatives with psychiatric disorder 0.75 (0.88) 0.48 (0.71) 1.04 (0.98) t(1,48) = 2.27*
Age of psychotic disorder onset 24.21 (6.70) 23.75 (7.36) 24.67 (6.10) t(1,48) = 0.47
Duration of illness (yr) 11.88 (7.71) 12.20 (8.95) 11.54 (6.43) t(1,48) = 0.30
Psychiatric diagnosis χ2(1) = 0.02
Schizophrenia 42 (84.2%) 22 (85.0%) 20 (83.3%)
Schizoaffective 8 (15.8%) 4 (15.0%) 4 (16.7%)
PANSS-Positive symptoms 11.37 (5.79) 10.79 (4.15) 11.83 (6.89) t(1,48) = 0.53
PANSS-Negative symptoms 14.00 (7.19) 12.57 (6.66) 15.11 (7.57) t(1,48) = 0.99
PANSS-General psychopathology 30.09 (12.46) 27.43 (11.77) 32.16 (12.91) t(1,48) = 1.08
Insight 2.10 (1.37) 1.62 (1.04) 2.44 (1.50) t(1,48) = 1.81
Fisrt degree relatives with SUD U = 180.00**
None 30 23 7
(Continued )
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(see Table 3). The significant independent variables related to the different task were premor-
bid IQ, GAF, negative symptoms (PANSS), severity (DAST-20) and duration of SUD. Premor-
bid IQ explained 39% of the variance of working memory task and, together with duration of
SUD, 57% of the variance of WCST. Execution is better as higher OQ and shorter duration of
SUD. Furthermore, GAF explained 13% of the variance in the Backward Digits subtest, being
the execution higher as better global functioning. Negative symptoms with DAST-20 described
24% of the variance of ToH test, patients with less negative symptoms and higher severity of
addiction performed better. Considering the executive functioning (composite score), premor-
bid IQ, DAST-20 and duration of SUD accounted for 52% of their variance. The best com-
posite scores of executive functioning are related to higher IQ and severity of addiction and
shorter duration of SUD.
Table 1. (Continued)
DS (N = 50) DS- (N = 26) DS+ (N = 24) Statistical contrast
One 6 3 3
Two or more 14 0 14
Age of intake onset (yr) 17.22 (5.20) 17.64 (5.88) 16.79 (4.47) t(1,48) = 0.57
Duration of SUD (yr) 18.39 (8.13) 17.97 (9.01) 18.83 (7.28) t(1,48) = 0.37
Primary drug of dependence χ2(3) = 1.14
Alcohol 24 (48.0%) 11 (42.3%) 13 (54.2%)
Cocaine 13 (26.0%) 8 (30.8%) 5 (20.8%)
Cannabis 10 (20.0%) 5 (19.2%) 5 (20.8%)
Other 3 (6.0%) 2 (7.7%) 1 (4.2%)
Number of substances used 3.80 (1.78) 3.31 (1.57) 4.26 (1.85) t(1,48) = 1.99
Cocaine a 47 (94.0%) 24 (92.3%) 23 (95.8%) χ2(1) = 0.27
Cannabis a 39 (78.0%) 20 (76.9%) 19 (79.2%) χ2(1) = 0.37
Alcohol a 41 (82.0%) 17 (65.4%) 24 (100%) χ2(1) = 10.13**
Psychodysleptics a 22 (44.0%) 10 (38.5%) 12 (50.0%) χ2(1) = 0.67
Opioids a 12 (24.0%) 4 (15.4%) 8 (33.3%) χ2(1) = 2.20
Sedatives a 10 (20.0%) 4 (15.4%) 6 (25.0%) χ2(1) = 0.72
Months of abstinence 6.64 (4.15) 6.50 (4.81) 6.79 (3.40) t(1,48) = 0.24
Number of relapses U = 211.50
None 18 11 7
One 10 7 3
Two or more 22 8 14
Severity of SUD (DAST-20) 12.00 (2.62) 12.67 (2.96) 11.43 (2.24) t(1,48) = 1.21
Intermediate 26.9 25.0 28.6
Substantial 69.2 66.7 71.4
Severe 3.8 8.3 0
Daily number of cigarettes 20.50 (13.49) 16.08 (11.52) 25.29 (14.04) t(1,48) = 2.54*
Nicotine dependence (Fagerstro¨m test) 5.82 (2.77) 5.00 (2.73) 6.71 (2.57) t(1,48) = 2.28*
Daily caffeine intake (mg) 255.51 (203.67) 217.69 (179.58) 300.00 (219.41) t(1,48) = 1.45
CPZ = Chlorpromazine; BDI = Beck Depression Inventory; SASS = Social Adaptation Self-Evaluation Scale; PANSS = Positive and Negative Syndrome
Scale; SUD = Substance Use Disorder; DAST-20 = Drug Abuse Screening Test.
a Percentages will not equal 100 as each participant may take more than one substance or medication and may have more than one medical comorbidity.
*p < 0.05
**p < 0.01.
doi:10.1371/journal.pone.0169943.t001
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In the DS- group, similarly to the total sample, premorbid IQ was significant for Backward
Digits subtest, explaining 47% of the variance and, together with duration of SUD described
52% of the variance of WCST. In both cases higher IQ was related to better performance, and
in the second case with the shorter duration of SUD. On the other hand, DAST-20 described
48% of the variance of ToH test and months of abstinence and SUD relapses accounted for
31% of the variance in TMT-B. The planning ability is better as higher severity of addiction
and the superior cognitive flexibility as more months of abstinence and lower relapses. Consid-
ering the DS+ group, also premorbid IQ explained the variance in Backward Digits subtest,
in this case 26%. As higher IQ, the better the performance in working memory. Additionally,
IQ together with duration of SUD explained 47% of the variance in TMT-B and 36% of the
Table 2. Neuropsychological tests data in Z scores of Dual Schizophrenia (DS) patients, and considering the presence (DS+) or absence (DS-) of
suicide attempts. Mean, standard error and statistical contrast carried out (ANCOVA or MANCOVA with age as covariate).
Neuropsychological Tests DS (N = 50) DS- (N = 26) DS+ (N = 24) F(1,47) Effect size Power
PREMORBID IQ
Vocabulary (WAIS-III) -0.14 (0.11) -0.02 (0.15) -0.27 (0.16) 1.272
Block Design (WAIS-III) -0.17 (0.15) -0.21 (0.20) -0.13 (0.22) 0.071
Composite Summary Score -0.16 (0.12) -0.12 (0.16) -0.20 (0.17) 0.130
EXECUTIVE FUNCTIONING
Working Memory (Backward digits, WAIS-III) 0.03 (0.19) 0.10 (0.26) -0.10 (0.28) 0.634
Set-shifting / Cognitive Flexibility (TMT- B) -1.03 (0.12) -1.00 (0.18) -1.07 (0.18) 0.060
Planning abilities (Tower of Hanoi)
Number of movements 0.32 (0.14) 0.36 (0.19) 0.28 (0.20) 0.092
Reaction time -1.24 (0.20) -1.21 (0.28) -1.28 (0.30) 0.031
Global score -0.46 (0.15) -0.42 (0.20) -0.50 (0.21) 0.065
Abstract reasoning/Problem solving (WCST)
Trials -0.69 (0.16) -0.37 (0.22) -1.01 (0.24) 3.755
Total correct 0.59 (0.16) 0.52 (0.22) 0.66 (0.23) 0.184
Total errors -0.34 (0.14) -0.08 (0.19) -0.61 (0.20) 3.767
Perseverative errors 0.41 (0.18) 0.66 (0.26) 0.16 (0.27) 1.777
Non-perseverative errors -0.76 (0.12) -0.53 (0.16) -1.00 (0.17) 3.898
Conceptual level responses -0.49 (0.15) -0.22 (0.21) -0.77 (0.21) 3.459
Categories completed -0.74 (0.24) -0.05 (0.34) -1.42 (0.35) 8.013** 0.146 0.792
Trials to first category -1.12 (0.34) -0.36 (0.47) -1.88 (0.49) 4.969* 0.096 0.598
Failure to maintain set -0.69 (0.20) -0.43 (0.28) -0.96 (0.29) 1.678
Learn to learn -0.24 (0.21) 0.15 (0.28) -0.63 (0.30) 3.631
Global score -0.43 (0.13) -0.06 (0.18) -0.80 (0.19) 7.940** 0.145 0.788
Decision-making (Iowa Gambling Task)
Block 1 (trials 1–20) 0.40 (0.10) 0.55 (0.13) 0.25 (0.14) 2.744
Block 2 (21–40) -0.28 (0.08) -0.26 (0.11) -0.31 (0.12) 0.098
Block 3 (41–60) -0.59 (0.10) -0.32 (0.14) -0.87 (0.15) 7.790** 0.142 0.781
Block 4 (61–80) -0.66 (0.12) -0.37 (0.17) -0.95 (0.17) 5.636* 0.103 0.651
Block 5 (81–100) -0.57 (0.11) -0.21 (0.15) -0.93 (0.16) 10.457** 0.182 0.886
Total score (100 trials) -0.47 (0.09) -0.18 (0.12) -0.76 (0.13) 11.249** 0.193 0.907
Composite Summary Score -0.48 (0.07) -0.31 (0.10) -0.65 (0.10) 5.699* 0.105 0.685
IQ = intelligence quotient; WAIS-III = Wechsler Adult Intelligence Scale-Revised Third Edition; TMT-B = Trail Making Test, trail B; WCST = Wisconsin Card
Sorting Test
* p < 0.05
**p < 0.01.
doi:10.1371/journal.pone.0169943.t002
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variance in WCST. In both cases, as higher is the IQ better is the execution and as shorter
duration of SUD better cognitive flexibility. Finally, negative symptoms described 38% of the
variance in ToH task, as higher presence of symptoms worse the performance. For the execu-
tive functioning (composite score), in the DS- group premorbid IQ, DAST-20 and duration of
SUD explained the 87% of its variance, while in the DS+ group IQ together with duration of
SUD accounted for the 52% (see Table 3). In all cases the sense of the relationship is established
as described in the total sample.
We found significant correlations between current suicide risk and number of first-degree
relatives with SUD and insight, which accounted for 64% of the variance for the total sample.
Fig 1. Total score (100 trials) (a) and learning (b) in Iowa Gambling task (IGT) for Dual Schizophrenia
patients with (DS+) and without (DS-) suicide attempts. B1: trials 1–20; B2: trials 21–40; B3: trials 41–60;
B4: trials 61–80; B5: trials 81–100.
doi:10.1371/journal.pone.0169943.g001
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When considering the groups this result correspond to the DS+ patients, with first-degree rela-
tives with SUD and insight together explaining the 87% of their variance for current suicide
risk. In contrast, in DS- group the 47% of the variance of current suicide risk was explained for
the positive symptoms (PANSS) (Table 4).
Discussion
To our knowledge, this is the first study aiming to explore the executive functioning, current
suicide risk and clinical state in DS patients, considering the presence or absence of lifetime
suicide attempts and related factors.
Table 3. Stepwise linear regression analysis of each independent variable, explaining executive functioning of Dual Schizophrenia (DS) patients,
and considering the presence (DS+) or absence (DS-) of suicide attempts.
Executive functioning Adjusted R2 F Independent variables a β Standardized p values Condition indexb
DS (N = 50)
Working Memory (Backward digits, WAIS-III) 0.393 30.464 Premorbid IQ 0.627 0.001 1.205
Set-shifting / Cognitive Flexibility (TMT- B) 0.127 7.952 GAF 0.380 0.007 12.281
Planning Abilities (ToH) 0.241 4.813 Negative symptoms (PANSS) -0.474 0.015 10.800
Severity of SUD (DAST-20) 0.397 0.049
Abstract Reasoning / Problem Solving (WCST) 0.574 9.092 Premorbid IQ 0.499 0.001 4.880
Duration of SUD (yr) -0.606 0.002
Composite summary score 0.522 6.014 Premorbid IQ 0.592 0.006 10.804
Severity of SUD (DAST-20) 0.581 0.008
Duration of SUD (yr) -0.505 0.028
DS- (N = 26)
Working Memory (Backward digits, WAIS-III) 0.465 22.758 Premorbid IQ 0.698 0.001 1.550
Set-shifting / Cognitive Flexibility (TMT- B) 0.305 6.274 Months of abstinence 0.515 0.006 4.008
SUD relapses 0.378 0.041
Planning Abilities (ToH) 0.483 5.532 Severity of SUD (DAST-20) 0.875 0.008 7.570
Abstract Reasoning / Problem Solving (WCST) 0.522 6.996 Premorbid IQ 0.447 0.014 4.390
Duration of SUD (yr) -0.751 0.006
Composite summary score 0.872 12.311 Premorbid IQ 0.781 0.019 10.168
Severity of SUD (DAST-20) 0.957 0.005
Duration of SUD (yr) -0.499 0.041
DS+ (N = 24)
Working Memory (Backward digits, WAIS-III) 0,260 8.713 Premorbid IQ 0,542 0.008 1.267
Set-Shifting / Cognitive Flexibility (TMT- B) 0.466 10.583 Duration of SUD (yr) -0.741 0.001 6.398
Premorbid IQ 0.682 0.001
Planning Abilities (ToH) 0.380 4.676 Negative symptoms (PANSS) -0.760 0.012 4.245
Abstract Reasoning / Problem Solving (WCST) 0.356 7.968 Premorbid IQ 0.524 0.010 6.305
Duration of SUD (yr) -0.436 0.016
Composite summary score 0.517 4.209 Premorbid IQ 0.726 0.014 6.195
Duration of SUD (yr) -0.465 0.029
WAIS-III = Wechsler Adult Intelligence Scale-Revised Third Edition; IQ = Intelligence Quotient; TMT-B = Trail Making Test, trail B; GAF = Global
Assessment of Functioning; ToH = Tower of Hanoi; PANSS = Positive and Negative Syndrome Scale; SUD = Substance Use Disorder; DAST-20 = Drug
Abuse Screening Test; WCST = Wisconsin Card Sorting Test; IGT = Iowa Gambling Task.
a Only significant variables are presented that comprise each explicative model.
b
. In models with more than one variable is included the superior.
In all cases, the Tolerance values were higher than 0.815 and the Variance Inflation Factor values lower than 1.209.
doi:10.1371/journal.pone.0169943.t003
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We did not find differences in any sociodemographic variables or in most of the clinical
ones between DS+ and DS- patients. The only differences observed were that the DS+ group
showed a higher number of daily cigarette intake and more nicotine dependence, greater rates
of alcohol consumption and use of interdictors, which may be due to the need to relieve the
dysphoric mood in these patients [24, 52, 53].
The groups neither showed significant differences in current suicide risk scores, although
we observed more patients in DS+ than in DS- group fulfilling the risk criteria. Regarding
pharmacological treatment, the literature suggests that typical antipsychotics are more related
to suicidality due to their side effects, while atypical antipsychotics reduce the rates of attempts
[54]. However, and in line with other authors [9], we did not find differences in typical or atyp-
ical antipsychotic prescriptions between groups, or in CPZ. Furthermore, we did not find dif-
ferences in GAF or CGI-S scores, depressive or psychotic symptoms or in social adaptation,
suggesting similar psychosocial functioning in both groups at the moment of assessment. The
good clinical condition of patients and the similarity between groups is due to the schizophre-
nia stabilization as well as to SUD treatment in which is worked therapeutically the presence of
psychiatric symptomatology by means of an integrated treatment which seems advantageous
compared to specific interventions in DS [5]. The absence of differences between groups in
clinical variables, which is known may influence the cognitive performance, supports the valid-
ity of our results in relation to lifetime suicide attempts and executive functions. It is possible
that the consideration of patients with less demanding treatments and less abstinence time
contributes to greater differences between groups, which should be explored in future studies.
Although precedent studies about neurocognition in DS are heterogeneous, it has been
observed that DS patients are characterized by a worse global cognitive state [26], which is age-
related, especially in executive performance [2, 3, 27] compared to single SZ. Regarding life-
time suicide attempts, in some studies that pointed out a better functioning in SZ patients with
this condition related to the ability to initiate and plan suicidal behavior [29, 30], little informa-
tion about the comorbidity with SUD was considered. In our study, while DS patients showed
relative good global executive performance compared to normative data, they presented a spe-
cifically impaired functioning in set-shifting, planning abilities and problem solving skills. On
the other hand, when groups are considered, DS+ patients showed worse general executive
functioning and low performance for both problem solving skills and disadvantageous deci-
sion-making, without differences in premorbid IQ. Our results suggest that previous life time
suicide attempts are related to executive deficits, although we cannot discard that other general
cognitive deficits (i.e. attention) are also involved. In line with prior studies [9, 19, 28], these
results suggest that the previous lifetime suicide attempts could increase the dysfunctional
Table 4. Stepwise linear regression analysis of each independent variable explaining current suicide risk of Dual Schizophrenia (DS) patients,
and considering the presence (DS+) or absence (DS-) of suicide attempts.
Suicide risk (Plutchik scale) Adjusted R2 F Independent variables a β Standardized p values Condition indexb
DS (N = 50) 0.644 18.090 First-degree relatives with SUD 0.601 0.001 4.199
Insight (PANSS) 0.413 0.007
DS- (N = 26) 0.467 10.650 Positive symptoms (PANSS) 0.718 0.009 5.916
DS+ (N = 24) 0.870 37.747 First-degree relatives with SUD 0.718 0.001 5.019
Insight (PANSS) 0.442 0.007
SUD = Substance Use Disorder; PANSS = Positive and Negative Syndrome Scale.
a Only significant variables are presented that comprise each explicative model.
b In models with more than one variable is included the superior.
In all cases, the Tolerance values were higher than 0.890 and the Variance Inflation Factor values lower than 1.124.
doi:10.1371/journal.pone.0169943.t004
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impulsivity. Nevertheless, as it has been previously described [20, 31], we found that alcohol
consumption accounts for the problem solving skills impairment. Thus, it seems essential to
consider the main substance of dependence for a better limitation of the executive functioning
in DS and the impact of lifetime suicide attempts on it.
We want to note that the lack of differences in executive functioning in a SZ sample with or
without lifetime suicide attempts found in some studies [9, 55] may be due to the low sensitiv-
ity of the neuropsychological tasks used. In contrast, the IGT and WCST used in our study
could be good measures to elucidate impairments in both orbitofrontal and dorsolateral func-
tioning in patients with lifetime suicide attempts, although the influence of alcohol depen-
dence in problem solving needs to be further explored. Furthermore, in our sample, the DS
+ group had more first-degree relatives with SUD or a psychiatric illness, suggesting there may
be an influence of genetic liability or social environmental factors in suicide attempts [17].
Moreover, several factors modulate executive performance of DS patients. Thus, the sever-
ity of SUD seems to play a positive influence on executive functioning and specifically in plan-
ning abilities, in contrast to negative symptoms. The result of the DS- group indicates that this
is probably due to the necessity to obtain substances to maintain drug use in subjects with a
stronger addiction [9, 28, 31], which could somehow mitigate their negative affectivity. More-
over, patients with greater severity of SUD require often treatment younger than those with
less severity and, therefore, their cognitive functioning could be more preserved of the neuro-
toxic damage associated with the consumption [3, 31]. However, the results in the DS+ group
suggest that negative symptoms may hinder planning for achieving life goals and quality of life
[56], which in previous studies has been associated with suicide attempts [18]. However, in the
DS- group we found the positive symptoms associated with the current risk suicide, possibly
due to an increased impulsivity [9, 17, 27]. Furthermore, in DS patients the duration of SUD
was related to cognitive impairment on general executive performance and with problem solv-
ing and set-shifting abilities [6] and the poor psychosocial functioning was related to set-shift-
ing difficulties, which could increase the difficulty of rehabilitation [26]. It is noteworthy that
the premorbid IQ could be a crucial neuroprotector factor [50] for working memory, problem
solving and global executive functioning of DS patients, independently of lifetime suicide
attempts, as well as for cognitive flexibility in DS+. On the other hand, in the DS- group better
set-shifting performance appears related to both longer abstinence period and higher SUD
relapses. In this way, the assessment of executive functions and the consideration of clinical
risk factors for integrating cognitive remediation therapy could be beneficial for the effective-
ness of treatment and clinical course of DS patients [26], especially for those DS+ or with
suicide risk, similarly to that hypothesized in SZ [57], and could be determinant for a better
prognosis in social and occupational function.
Our results highlight the importance for the greater suicide risk score of having more
insight and first-degree relatives with SUD in DS+, suggesting the hypothesis that these
patients are more vulnerable to the perception of stigma, which increases the future probability
of suicide attempts [14, 29]. Even though we have addressed this current knowledge gap in DS
individuals, some limitations should be taken into account when interpreting our results: (i)
The suicide attempts were collected retrospectively and self-reported by patients, without
recorded the method of attempted and its seriousness. Although we contrasted this informa-
tion with medical records and their treating psychiatrist, we do not exclude that such informa-
tion might be biased; (ii) The clinical and neuropsychological assessment took place after the
individuals had intended suicide; and the results must be understood as associated factors with
suicidality; (iii) Our sample is comprised by a relatively small number of patients although
higher than most previous studies with DS patients, who often willing to drop out from studies
or declining to participate in them. Moreover, the analysis with multiple comparisons without
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corrections also could increase the probability of false positive results and the low power in
some analyses, especially when considering the alcohol dependence, could increase the proba-
bility of false negative results. Controlling for diverse confounding variables with our inclu-
sion/exclusion criteria as well as the exhaustive clinical and cognitive evaluation reinforce the
obtained results, although future research is needed to overcome the limitations of this study.
Conclusions
Our results emphasize the importance of taking into consideration the clinical and cognitive
factors that modulate the suicidality in DS, in order to prevent future suicide attempts and to
develop targeted interventions to reduce such risk, although further studies are needed to pro-
vide more consistent conclusions. The DS+ group presented worse general executive function-
ing, decision-making abilities and problem solving skills, although the last one was influenced
by alcohol consumption. Several clinical factors, such as global psychosocial functioning, nega-
tive symptoms, SUD characteristics (severity, duration, abstinence period and relapses), and
premorbid IQ modulated executive functioning in DS patients. Furthermore, first-degree rela-
tives with SUD, insight scores and positive symptoms were positively associated with suicide
risk scores. Our results can be not generalized, having to be taken with caution since it is the
first study made in this line and it is not exempt of some methodological limitations. Future
works should examine the therapeutic benefit of including neurocognitive remediation ther-
apy when necessary in the integrated treatment of DS patients.
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